Close Menu

Plexxikon

This week, Certara said that Plexxikon has selected its D360 software solution to support data access and analysis for its drug discovery projects.

By Adam Bonislawski
Two papers published in the current edition of Nature Biotechnology add significantly to the publicly available data on the specificity of kinase inhibitors.

Originally published Sept. 12.
By Turna Ray

Since BRAF inhibitors such as Roche/Plexxicon's vemurafenib, or PLX 4032, are currently in clinical trials for melanoma patients, the authors think there could be a rapid transition of their findings to the clinic.

By exploring a treatment strategy that involves Roche/Plexxikon's investigational pharmacogenomically targeted drug vemurafenib and Bristol-Myers Squibb's newly approved melanoma treatment Yervoy, two large drug developers are hoping to further improve outcomes for a genomically defined patient population.

Pages

The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.

US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.

Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.

In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.